Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells

Life Sciences

Volumn 71, Issue 23, 2002, Pages 2729-2740

  Li, Y C ^a   Fung, K P ^a   Kwok, T T ^a   Lee, C Y ^a   Suen, Y K ^a   Kong, S K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Drug resistance; Lonidamine; Mitochondria; P glycoprotein

Indexed keywords

CYTOCHROME C; DNA FRAGMENT; DOXORUBICIN; GLYCOPROTEIN P; LONIDAMINE; PHOSPHATIDYLSERINE;

APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER MITOCHONDRION; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, AGAR GEL; HUMANS; INDAZOLES; MITOCHONDRIA;

EID: 0037174915     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02103-3     Document Type: Article

References (37)

1. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:2002;153-164.
2. Kroemer G., Dallaporta B., Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 60:1998;619-642.
3. Gupta S. Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci. 69:2001;2957-2964.
4. Zimmermann K.C., Bonzon C., Green D.R. The machinery of programmed cell death. Pharmacol Ther. 92:2001;57-70.
5. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 15:2001;2922-2933.
6. Daugas E., Nochy D., Ravagnan L., Loeffler M., Susin S.A., Zamzami N., Kroemer G. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett. 476:2000;118-123.
7. van Loo G., Schotte P., van Gurp M., Demol H., Hoorelbeke B., Gevaert K., Rodriguez I., Ruiz-Carrillo A., Vandekerckhove J., Declercq W., Beyaert R., Vandenabeele P. Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Differ. 8:2001;1136-1142.
8. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 40:1997;S3-S8. Suppl.
9. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:1993;385-427.
10. Fardel O., Lecureur V., Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol. 27:1996;1283-1291.
11. Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:1994;539-542.
12. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood. 98:2001;2603-2614.
13. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry. 65:2000;95-106.
14. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 290:2000;989-992.
15. Sartorius U.A., Krammer P.H. Upregulation of bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer. 97:2002;584-592.
16. Ryan K.M., Phillips A.C., Vousden K.H. Regulation and function of p53 tumor suppressor protein. Curr Opin Cell Biol. 13:2001;332-337.
17. Wallace-Brodeur R.R., Lowe S.W. Clinical implications of p53 mutations. Cell. Mol. Life Sci. 55:1999;64-75.
18. Makin G., Hickman J.A. Apoptosis and cancer chemotherapy. Cell Tissue Res. 301:2000;143-152.
19. Szewczyk A., Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev. 54:2002;101-127.
20. Decaudin D., Marzo I.I., Brenner C., Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy. Int J Oncol. 12:1998;141-152.
21. Ravagnan L., Marzo I., Costantini P., Susin S.A., Zamzami N., Petit P.X., Hirsch F., Goulbern M., Poupon M.F., Miccoli L., Xie Z., Reed J.C., Kroemer G. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene. 18:1999;2537-2546.
22. Nakayama G.R., Caton M.C., Nova M.P., Parandoosh Z. Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods. 204:1997;205-208.
23. Suen Y.K., Fung K.P., Choy Y.M., Lee C.Y., Chan C.W., Kong S.K. Concanavalin A induced apoptosis in murine macrophage PU5-1.8 cells through clustering of mitochondria and release of cytochrome c. Apoptosis. 5:2000;369-377.
24. Ko S., Yuen W.F., Fung K.P., Lee C.Y., Choy Y.M., Cheng H.K., Kwok T.T., Kong S.K. Reversal of TNF-alpha resistance by hyperthermia: role of mitochondria. Life Sci. 67:2000;3113-3121.
25. Kruh G.D., Goldstein L.J. Doxorubicin and multidrug resistance. Curr Opin Oncol. 5:1993;1029-1034.
26. Belzacq A.S., El Hamel C., Vieira H.L., Cohen I., Haouzi D., Metivier D., Marchetti P., Brenner C., Kroemer G. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene. 20:2001;579-587.
27. Suen Y.K., Fung K.P., Lee C.Y., Kong S.K. Gliotoxin induces apoptosis in cultured macrophages via production of reactive oxygen species and cytochrome c release without mitochondrial depolarization. Free Radic Res. 35:2001;1-10.
28. Zamzami N., Marchetti P., Castedo M., Zanin C., Vayssiere J.L., Petit P.X., Kroemer G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med. 181:1995;1661-1672.
29. Salvioli S., Ardizzoni A., Franceschi C., Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett. 411:1997;77-82.
30. Homolya L., Hollo Z., Germann U.A., Pastan I., Gottesman M.M., Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem. 268:1993;21493-21496.
31. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 184:1995;39-51.
32. Hoffman W.H., Biade S., Zilfou J.T., Chen J., Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 277:2002;3247-3257.
33. Luo D., Cheng S.C., Xie Y. Expression of Bcl-2 family proteins during chemo-therapeutic agents-induced apoptosis in the hepatoblastoma HepG2 cell line. Br J Biomed Sci. 56:1999;114-122.
34. Silvestrini B., Palazzo G., De Gregorio M. Lonidamine and related compounds. Prog Med Chem. 21:1984;110-135.
35. Forster R., Campana A., D'Onofrio E., Henderson L., Mosesso P., Scorza Barcellona P. Lonidamine: a non-mutagenic antitumor agent. Carcinogenesis. 11:1990;1509-1515.
36. Fanciulli M., Bruno T., Giovannelli A., Gentile F.P., Di Padova M., Rubiu O., Floridi A. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine. Clin Cancer Res. 6:2000;1590-1597.
37. Ben-Horin H., Tassini M., Vivi A., Navon G., Kaplan O. Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies. Cancer Res. 55:1995;2814-2821.